Annual report pursuant to Section 13 and 15(d)

Note 5 - Debt and Other Financing Arrangements

v3.10.0.1
Note 5 - Debt and Other Financing Arrangements
12 Months Ended
Jun. 30, 2018
Notes to Financial Statements  
Debt Disclosure [Text Block]
Note
5
. Debt and Other Financing Arrangements:
 
 
The Company entered into revolving line-of-credit facility governed by a Credit Agreement (the Credit Agreement) on
July 28, 2016.
The Credit Agreement provides for a revolving credit facility of
$400
million, which can be increased by an additional
$200
million subject to certain conditions. Borrowings under the Credit Agreement
may
be used for working capital and expenditures of the Company and its subsidiaries, including financing permitted acquisitions. Borrowings under the Credit Agreement for base rate loans bear interest at a variable rate equal to the greater of (i) the prime commercial rate, (ii) the per annum federal funds rate plus
0.5%,
or (iii) LIBOR +
1.00%
-
1.75%
depending on the existing total leverage ratio of Debt to Earnings Before Interest, Taxes, Depreciation and Amortization (as defined in the Credit Agreement). The annualized fee for any unused portion of the credit facility is currently
25
basis points.
 
The Credit Agreement would have matured on
July 
28,
2021
and contains customary restrictive and financial covenants and customary events of default. As of
June 
30,
2018,
the outstanding balance under the Credit Agreement was
$339.0
million.
 
In connection with the acquisition of Exosome Diagnostics, Inc. on
August 1, 2018,
the Company entered into a new credit facility that provides for a revolving credit facility of
$600
million, which can be increased by an additional
$200
million subject to certain conditions, and a term loan of
$250
million.  The credit facility is governed by a Credit Agreement dated
August 1, 2018 and matures on August 1, 2023.
This facility replaced the revolving line-of-credit facility mentioned above and bears interest at a variable rate.